Table 1.
Patient characteristics as N (%) or median (range)
| PHT | LEV | |
|---|---|---|
| N | 70 | 34 |
| Male sex | 46 (65.7) | 18 (52.9) |
| Age (years) | 58 (17–74) | 58 (35–69) |
| Diagnosis | ||
| AML | 40 (57.1) | 10 (29.4) |
| MDS | 24 (34.3) | 11 (32.4) |
| CML | 4 (5.7) | 3 (8.8) |
| PCNSL | 0 | 5 (14.7) |
| DLBCL | 2 (2.9) | 0 |
| Other | 0 | 5 (14.7) |
| Donor/stem cell source | ||
| Autologous peripheral blood | 0 | 5 (14.7) |
| Related peripheral blood | 14 (20.0) | 4 (11.8) |
| Unrelated peripheral blood | 0 | 5 (14.7) |
| Unrelated bone marrow | 42 (60.0) | 10 (29.4) |
| Unrelated cord blood | 14 (20.0) | 10 (29.4) |
| Conditioning regimen | ||
| ivBu/CY | 20 (28.6) | 9 (26.5) |
| FB4 | 8 (11.4) | 0 |
| ATG/FB4 ± AraC | 37 (52.9) | 18 (52.9) |
| FB4/TBI ± AraC | 2 (2.9) | 4 (11.8) |
| ivBu2 + α | 3 (4.3) | 0 |
| ivBu4 + β | 0 | 3 (8.8) |
| Emesis prophylaxis | ||
| Granisetron | 70 (100) | 10 (29.4) |
| Palonosetron | 0 | 1 (2.9) |
| Palonosetron + fosaprepitant | 0 | 23 (67.6) |
AML acute myeloid leukemia, MDS myelodysplastic syndrome, CML chronic myeloid leukemia, PCNSL primary central nervous system lymphoma, DLBCL diffuse large B cell lymphoma, ivBu/CY intravenous busulfan at 12.8 mg/kg + cyclophosphamide, ivBu2 + α intravenous busulfan at 6.4 mg/kg + other drugs, FB4 fludarabine + intravenous busulfan at 12.8 mg/kg, ATG anti-thymocyte globulin (rabbit), AraC cytarabine, TBI total body irradiation, ivBu4 + β intravenous busulfan at 12.8 mg/kg + other drugs, PHT phenytoin, LEV levetiracetam.